JAMESHA TUMBLIN: Open Payments
NPI 1083975742 · SMITHVILLE, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$455 in 22 payments from 9 companies in 2025. Trend: 2023 $642 · 2024 $550 · 2025 $455
Food & beverage: $435Education: $20
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 9 | $201 |
| Calliditas Therapeutics US Inc. | 2 | $56 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $50 |
| Aurinia Pharma U.S., Inc. | 2 | $44 |
| AstraZeneca Pharmaceuticals LP | 2 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| OPKO Pharmaceuticals, LLC | 1 | $20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $19 |
| AKEBIA THERAPEUTICS INC | 1 | $17 |
Products named: Fabhalta, Vanrafia, TARPEYO, Kerendia, LUPKYNIS, JYNARQUE, RAYALDEE, JARDIANCE.
Industry payments across MS — which companies pay providers there.
